EKF Diagnostics (LON:EKF) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next?

Shares of EKF Diagnostics Holdings plc (LON:EKF) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 25.43 and traded as high as GBX 27. EKF Diagnostics shares last traded at GBX 26.80, with a volume of 39,465 shares trading hands.

Analyst Ratings Changes

Separately, Stifel Nicolaus restated a “buy” rating and issued a GBX 35 price target on shares of EKF Diagnostics in a research report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, EKF Diagnostics presently has a consensus rating of “Buy” and an average price target of GBX 35.

EKF Diagnostics Price Performance

The company has a debt-to-equity ratio of 2.01, a quick ratio of 1.77 and a current ratio of 4.16. The company has a market capitalization of £115.37 million, a price-to-earnings ratio of 57.02 and a beta of 0.52. The company has a 50-day moving average price of GBX 25.79 and a 200-day moving average price of GBX 25.43.

EKF Diagnostics (LON:EKF) last announced its quarterly earnings results on Tuesday, March 24th. The company reported GBX 0.47 earnings per share for the quarter. EKF Diagnostics had a net margin of 4.12% and a return on equity of 3.01%. On average, equities research analysts expect that EKF Diagnostics Holdings plc will post 2.2987842 EPS for the current fiscal year.

About EKF Diagnostics

EKF is an AIM-listed global diagnostics business focussed on:

● Point-of-Care analysers in the key areas of Hematology and Diabetes

● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.